Estrogen Receptor Modulators
"Estrogen Receptor Modulators" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that possess antiestrogenic actions but can also produce estrogenic effects as well. They act as complete or partial agonist or as antagonist. They can be either steroidal or nonsteroidal in structure.
Descriptor ID |
D020847
|
MeSH Number(s) |
D06.347.360 D27.505.696.399.450.360
|
Concept/Terms |
Estrogen Receptor Modulators- Estrogen Receptor Modulators
- Modulators, Estrogen Receptor
- Receptor Modulators, Estrogen
- Antiestrogens
- Antiestrogen
- Estrogen Receptor Modulator
- Modulator, Estrogen Receptor
- Receptor Modulator, Estrogen
|
Below are MeSH descriptors whose meaning is more general than "Estrogen Receptor Modulators".
Below are MeSH descriptors whose meaning is more specific than "Estrogen Receptor Modulators".
This graph shows the total number of publications written about "Estrogen Receptor Modulators" by people in this website by year, and whether "Estrogen Receptor Modulators" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 1 | 0 | 1 |
2001 | 1 | 0 | 1 |
2017 | 2 | 1 | 3 |
2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Estrogen Receptor Modulators" by people in Profiles.
-
Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection. Cell Death Differ. 2022 01; 29(1):156-166.
-
Estrogen Receptor Modulators in Viral Infections Such as SARS-CoV-2: Therapeutic Consequences. Int J Mol Sci. 2021 Jun 18; 22(12).
-
Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a meta-analysis of randomized controlled trials. Arch Womens Ment Health. 2018 02; 21(1):31-41.
-
Effects of tibolone on fibrinogen and antithrombin III: A systematic review and meta-analysis of controlled trials. Pharmacol Res. 2017 Oct; 124:64-73.
-
Resveratrol as MDR reversion molecule in breast cancer: An overview. Food Chem Toxicol. 2017 May; 103:223-232.
-
[Evolvement of hormone therapy for breast cancer. Florence, March 14, 2001]. Tumori. 2001 May-Jun; 87(3):A6-14.
-
[Anastrozolo: intracellular anti-aromatase activity and pharmacologic interactions. Satellite Symposium AIOM 1999 - Roma]. Tumori. 1999 Nov-Dec; 85(6):A19-25.